Key result
Treatment with rHIgM22 for 5 weeks significantly decreased T2 high signal lesion volume on spinal cord MRI in a virus-induced murine model of multiple sclerosis.
Why the study?
Does the human monoclonal antibody rHIgM22 decrease lesion volume as detected by MRI in a virus-induced murine model of multiple sclerosis?
Population
Virus-induced murine model of multiple sclerosis
Design
Preclinical
Follow-up
5 weeks
Authors
Loading...
Hypothesis-generating for remyelination therapies in MS; extends murine lesion data but requires human trials before any clinical consideration.
Does the human monoclonal antibody rHIgM22 decrease lesion volume as detected by MRI in a virus-induced murine model of multiple sclerosis?
The human monoclonal antibody rHIgM22 significantly decreases T2 high signal lesion volume on MRI, which correlates with histologic remyelination in a murine model of multiple sclerosis.
Pirko et al. (2004) studied virus-induced murine model of multiple sclerosis. rHIgM22 was evaluated on T2 high signal lesion volume. Treatment with rHIgM22 for 5 weeks significantly decreased T2 high signal lesion volume on spinal cord MRI in a virus-induced murine model of multiple sclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: